Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice

Journal of Neuroscience Research

Volumn 86, Issue 8, 2008, Pages 1748-1757

  Denovan Wright, Eileen M ^a   Attis, Marissa ^a   Rodriguez Lebron, Edgardo ^b   Mandel, Ronald J ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cannabinoid receptors; NGFI A; Preproenkephalin; Recombinant adeno associated virus; Striatal transcripts

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; HUNTINGTIN; PARVOVIRUS VECTOR;

ABNORMAL BEHAVIOR; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; CILIARY NEUROTROPHIC FACTOR; CORPUS STRIATUM; DOWN-REGULATION; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; MOTOR SKILLS DISORDERS; TIME FACTORS;

EID: 45549109815     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21636     Document Type: Article

References (55)

1. Adler R, Landa KB, Manthorpe M, Varon S. 1979. Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science 204:1434-1436.
2. Arakawa Y, Sendtner M, Thoenen H. 1990. Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines. J Neurosci 10:3507-3515.
3. Bachoud-Levi AC, Deglon N, Nguyen JP, Bloch J, Bourdet C, Winkel L, Remy P, Goddard M, Lefaucheur JP, Brugieres P, Baudic S, Cesaro P, Peschanski M, Aebischer P. 2000. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 11:1723-1729.
4. Bloch J, Bachoud-Levi AC, Deglon N, Lefaucheur JP, Winkel L, Palfi S, Nguyen JP, Bourdet C, Gaura V, Remy P, Brugieres P, Boisse MF, Baudic S, Cesaro P, Hantraye P, Aebischer P, Peschanski M. 2004. Neuroprotective gene therapy for Huntington's disease, using polymerencapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15:968-975.
5. Bok D, Yasumura D, Matthes MT, Ruiz A, Duncan JL, Chappelow AV, Zolutukhin S, Hauswirth W, LaVail MM. 2002. Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp Eye Res 74:719-735.
6. Bonni A, Greenberg ME. 1997. Neurotrophin regulation of gene expression. Can J Neurol Sci 24:272-283.
7. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N. 2004. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302-317.
8. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ. 1999. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257.
9. Cha JHJ. 2000. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23:387-392.
10. de Almeida LP, Zala D, Aebischer P, Deglon N. 2001. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 8:433-446.
11. Denovan-Wright EM, Rodriguez-Lebron E, Lewin AS, Mandel RJ. 2007. Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. Neurobiol Dis. (Epub ahead of print).
12. Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR, Sutcliffe JG, Thomas EA. 2006. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96:743-757.
13. Ditzler S, Stoeck J, LeBlanc M, Kooperberg C, Hansen S, Coppin L, Olson JM. 2003. A rapid neurobehavioral assessment reveals that FK506 delays symptom onset in R6/2 Huntington's disease mice. Preclinica 1:115-126.
14. Emerich DF. 2004. Dose-dependent neurochemical and functional protection afforded by encapsulated CNTF-producing cells. Cell Transplant 13:839-844.
15. Emerich DF, Thanos CG. 2006. Intracompartmental delivery of CNTF as therapy for Huntington's disease and retinitis pigmentosa. Curr Gene Ther 6:147-159.
16. Emerich DF, Winn SR. 2004. Neuroprotective effects of encapsulated CNTF-producing cells in a rodent model of Huntington's disease are dependent on the proximity of the implant to the lesioned striatum. Cell Transplant 13:253-259.
17. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP. 2003. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289:1826-1832.
18. Gomez GT, Hu H, McCaw EA, Denovan-Wright EM. 2006. Brain-specific factors in combination with mutant huntingtin induce gene-specific transcriptional dysregulation. Mol Cell Neurosci 31:661-675.
19. Hebb ALO, Robertson HA, Denovan-Wright EM. 2004. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123:967-981.
20. Hefti F. 1997. Neurotrophic factor therapy - keeping score. Nature Med 3:497-498.
21. Henderson JT, Seniuk NA, Richardson PM, Gauldie J, Roder JC. 1994. Systemic administration of ciliary neurotrophic factor induces cachexia in rodents. J Clin Invest 93:2632-2638.
22. Herzog CD, Dass B, Holden JE, Stansell J 3rd, Gasmi M, Tuszynski MH, Battus RT, Kordower JH. 2007. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22:1124-1132.
23. Hodges A, Hughes G, Brooks S, Elliston L, Holmans P, Dunnett SB, Jones L. 2007. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. Genes Brain Behav (in press).
24. Hu H, McCaw EA, Hebb AL, Gomez GT, Denovan-Wright EM. 2004. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 20:3351-3363.
25. Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
26. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. 2000. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20:4686-4700.
27. Kokoeva MV, Yin H, Flier JS. 2005. Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 310:679-683.
28. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R. 2007. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16:1845-1861.
29. Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ. 2001. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A 98:4652-4657.
30. Li SH, Li XJ. 2004. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20:146-154.
31. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha JHJ, Olson JM. 2000. Decreased expression of striatal signahng genes in a mouse model of Huntington's disease. Hum Mol Genet 9:1259-1271.
32. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM. 2002. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 11:1911-1926.
33. MacGibbon GA, Hamilton LC, Crocker SF, Costain WJ, Murphy KM, Robertson HA, Denovan-Wright EM. 2002. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice. J Neurosc Res 67:372-378.
34. Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Leff SE. 1998. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 18:4271-4284.
35. Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, Nash K, Burger C. 2006. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 13:463-483.
36. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.
37. McCaw EA, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM. 2004. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 271:4909-4920.
38. Miller RG, Bryan WW, Dietz MA, Munsat TL, Petajan JH, Smith SA, Goodpasture JC. 1996. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 47:1329-1331.
39. Mittoux V, Joseph JM, Conde F, Palfi S, Dautry C, Poyot T, Bloch J, Deglon N, Ouary S, Nimchinsky EA, Brouillet E, Hof PR, Peschanski M, Aebischer P, Hantraye P. 2000. Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther 11:1177-1187.
40. Naver B, Stub C, Moller M, Fenger K, Hansen AK, Hasholt L, Sorensen SA. 2003. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 122:1049-1057.
41. Neet KE, Campenot RB. 2001. Receptor binding, internalization, and retrograde transport of neurotrophic factors. Cell Mol Life Sci 58:1021-1035.
42. Peden CS, Burger C, Muzyczka N, Mandel RJ. 2004. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 78:6344-6359.
43. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. 2005. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 12:618-633.
44. Segal RA, Greenberg ME. 1996. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 19:463-489.
45. Sendtner M, Kreutzberg GW, Thoenen H. 1990. Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature 345:440-441.
46. Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A, Hedreen J, Sisodia S, Snyder SH, Dawson TM, Ryugo DK, Ross CA. 1995. Widespread expression of Huntington's-disease gene (It15) protein product. Neuron 14:1065-1074.
47. Sugars KL, Rubinsztein DC. 2003. Transcriptional abnormalities in Huntington disease. Trends Genet 19:233-238.
48. Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L, Wilson JM, Debyser Z, Baekelandt V. 2007. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18:195-206.
49. Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L. 2004. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 20:192-196.
50. Vergara C, Ramirez B. 2004. CNTF, a pleiotropic cytokine: emphasis on its myotrophic role. Brain Res Brain Res Rev 47:161-173.
51. Walling HW, Baldassare JJ, Westfall TC. 1998. Molecular aspects of Huntington's disease. J Neurosci Res 54:301-308.
52. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R. 1986. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 20:296-303.
53. Zala D, Bensadoun JC, Pereira de Almeida L, Leavitt BR, Gutekunst CA, Aebischer P, Hayden MR, Deglon N. 2004. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Exp Neurol 185:26-35.
54. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ Jr, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW, Flotte TR, Byrne BJ, Snyder RO. 2002. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28:158-167.
55. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattaneo E. 2003. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35:76-83.